Ophthalmic manifestations are associated with reduced tear lymphotoxin-α levels in chronic ocular graft-versus-host disease

Jiao Ma, Chendi Li, Yinghan Zhao, Zhan Shen, Bohao Hu, Rongmei Peng, Jing Hong, Jiao Ma, Chendi Li, Yinghan Zhao, Zhan Shen, Bohao Hu, Rongmei Peng, Jing Hong

Abstract

Purpose: To determine the role tear lymphotoxin-α (LT-α) in chronic ocular graft-versus-host disease (oGVHD).

Methods: Twenty-two chronic oGVHD and 17 control tear samples were collected, and commercial test strips were used to detect LT-α concentrations. Concentration differences between patients with and without oGVHD were determined via Mann-Whitney U test. The correlation between LT-α levels and ophthalmic parameters was analyzed using Spearman's test.

Results: The concentration of LT-α was significantly lower in oGVHD patients than in controls. LT-α levels were significantly correlated with OSDI, NIH eye score, T-BUT, and CFS among all participants. ROC analysis revealed that the area under the curve of LT-α was 0.847, and the cutoff value for chronic oGVHD diagnosis was 0.203 ng/mL.

Conclusion: Our study revealed the significant decrease of tear LT-α in oGVHD, and suggested LT-α as a promising marker for chronic oGVHD diagnosis.

Keywords: Biomarker; Lymphotoxin-α; Ocular graft-versus-host disease; Tear film.

Conflict of interest statement

The authors declare no competing interests in this work.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Tear LT-α concentration. A Tear concentration of LT-α was compared between patients with (n = 22) and without (n = 17) oGVHD. B-D Tear LT-α levels were compared between the male and female among all patients (B), oGVHD subpopulations (C), and controls (D). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 using Mann-Whitney U test
Fig. 2
Fig. 2
ROC curve of LT-α. Receiver operating characteristic (ROC) curve of tear LT-α to predict oGVHD. Area under the curve (AUC) = 0.8743; 95% CI (0.7502 to 0.9984); P < 0.0001

References

    1. Kassim A, Savani B. Hematopoietic stem cell transplantation for acute myeloid leukemia: a review. Hematol Oncol Stem Cell Ther. 2017;10:245–251. doi: 10.1016/j.hemonc.2017.05.021.
    1. Shikari H, Antin JH, Dana R. Ocular graft-versus-host disease: a review. Surv Ophthalmol. 2013;58:233–251. doi: 10.1016/j.survophthal.2012.08.004.
    1. Ferrara J, Levine J, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550–1561. doi: 10.1016/s0140-6736(09)60237-3.
    1. Anderson NG, Regillo C. Ocular manifestations of graft versus host disease. Curr Opin Ophthalmol. 2014;14:503–507. doi: 10.1097/01.icu.0000143684.22362.46.
    1. Jagasia M, Greinix H, Arora M, Williams K, Wolff D, Cowen E, Palmer J, Weisdorf D, Treister N, Cheng G, Kerr H, Stratton P, Duarte R, Mcdonald G, Inamoto Y, Vigorito A, Arai S, Datiles M, Jacobsohn D, Heller T, Kitko C, Mitchell S, Martin P, Shulman H, Wu R, Cutler C, Vogelsang G, Lee S, Pavletic S, Flowers M. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(389–401):e381. doi: 10.1016/j.bbmt.2014.12.001.
    1. Hu B, Qiu Y, Hong J. Tear cytokine levels in the diagnosis and severity assessment of ocular chronic graft-versus-host disease (GVHD) Ocul Surf. 2020;18:298–304. doi: 10.1016/j.jtos.2019.12.005.
    1. Jung JW, Han SJ, Song MK, Kim TI, Kim EK, Min YH, Cheong JW, Seo KY. Tear cytokines as biomarkers for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:2079–2085. doi: 10.1016/j.bbmt.2015.08.020.
    1. Cocho L, Fernández I, Calonge M, Martínez V, González-García M, Caballero D, López-Corral L, García-Vázquez C, Vázquez L, Stern M, Enríquez-de-Salamanca A. Biomarkers in ocular chronic graft versus host disease: tear cytokine- and chemokine-based predictive model. Invest Ophthalmol Vis Sci. 2016;57:746–758. doi: 10.1167/iovs.15-18615.
    1. Riemens A, Stoyanova E, Rothova A, Kuiper J. Cytokines in tear fluid of patients with ocular graft-versus-host disease after allogeneic stem cell transplantation. Mol Vis. 2012;18:797–802.
    1. Aggarwal B, Gupta S, Kim J. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651–665. doi: 10.1182/blood-2011-04-325225.
    1. Chiang E, Kolumam G, Yu X, Francesco M, Ivelja S, Peng I, Gribling P, Shu J, Lee WP, Refino C, Balazs M, Paler-Martinez A, Nguyen A, Young J, Barck K, Carano R, Ferrando R, Diehl L, Chatterjea D, Grogan J. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med. 2009;15:766–773. doi: 10.1038/nm.1984.
    1. Ware C, Crowe P, Grayson M, Androlewicz M, Browning J. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol. 1992;149:3881–3888.
    1. Browning J, Sizing I, Lawton P, Bourdon P, Rennert P, Majeau G, Ambrose C, Hession C, Miatkowski K, Griffiths D, Ngam-ek A, Meier W, Benjamin C, Hochman P. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J Immunol. 1997;159:3288–3298.
    1. Markey K, Burman A, Banovic T, Kuns R, Raffelt N, Rowe V, Olver S, Don A, Morris E, Pettit A, Wilson Y, Robb R, Randall L, Korner H, Engwerda C, Clouston A, Macdonald K, Hill G. Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood. 2010;115:122–132. doi: 10.1182/blood-2009-01-199927.
    1. Chiang E, Kolumam G, McCutcheon K, Young J, Lin Z, Balazs M, Grogan J. In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-disease. PLoS One. 2012;7:e33106. doi: 10.1371/journal.pone.0033106.
    1. Ma J, Shen Z, Peng R, Li C, Hu B, Hong J. Tear lipid metabolites as potential diagnostic biomarkers for ocular chronic graft-versus-host disease. Transplant cell Ther. 2021;27:232 e231–232 e236. doi: 10.1016/j.jtct.2020.12.018.
    1. Ruddle N. Lymphotoxin and TNF: how it all began-a tribute to the travelers. Cytokine Growth Factor Rev. 2014;25:83–89. doi: 10.1016/j.cytogfr.2014.02.001.
    1. Gaur U, Aggarwal B. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem Pharmacol. 2003;66:1403–1408. doi: 10.1016/s0006-2952(03)00490-8.
    1. Hirose T, Fukuma Y, Takeshita A, Nishida K. The role of lymphotoxin-alpha in rheumatoid arthritis. Inflamm Res. 2018;67:495–501. doi: 10.1007/s00011-018-1139-6.
    1. Lin X, Huang J, Liu Z. Large scale, prospective, multicenter, clinical evaluation of point-of-care Lymphotoxin alpha (LTA) test in dry eye disease. Invest Ophthalmol Vis Sci. 2020;61:116.
    1. Chen H, Chen H, Liang L, Zhong Y, Liang Y, Yu Y, Huang S, Lu X. Evaluation of tear protein markers in dry eye disease with different Lymphotoxin-alpha expression levels. Am J Ophthalmol. 2020;217:198–211. doi: 10.1016/j.ajo.2020.03.013.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel